Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q4 FY21 results · Jan–Mar 2021
Marksans Pharma reported revenue from operations of ₹330.20 crore (down 1.5% from Q4 FY20) and net profit of ₹79.50 crore (up 86.0% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a consolidated basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 330.20 | 335.35 | −1.5% | 358.36 | −7.9% |
| Other income | 6.01 | 0.03 | 231x | (3.17) | Turned profit |
| Total income | 336.21 | 335.38 | +0.2% | 355.19 | −5.3% |
| Profit before tax | 97.22 | 57.56 | +68.9% | 77.64 | +25.2% |
| Net profit for the period | 79.50 | 42.74 | +86.0% | 58.94 | +34.9% |
| EPS, basic (₹) | 1.93 | 1.00 | +93.0% | 1.42 | +35.9% |
| Net margin (%) | 24.1 | 12.7 | 16.4 |
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 137.58 | 113.64 | +21.1% | 168.46 | −18.3% |
| Other income | 11.91 | (0.08) | Turned profit | 6.24 | +90.8% |
| Total income | 149.49 | 113.55 | +31.6% | 174.70 | −14.4% |
| Profit before tax | 32.40 | 13.17 | +146.0% | 35.99 | −10.0% |
| Net profit for the period | 23.69 | 7.41 | +219.6% | 29.10 | −18.6% |
| EPS, basic (₹) | 0.58 | 0.18 | +222.2% | 0.71 | −18.3% |
| Net margin (%) | 17.2 | 6.5 | 17.3 |
Consolidated
- Filed with BSE
- 01 Jun 2021, 08:24 IST
- Board meeting
- 31 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Jun 2021, 08:24 IST
- Board meeting
- 31 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE